"metastatic cancer" trang 2 - tải miễn phí từ tailieuXANH
Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer

Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer
10    53    0
Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: Retrospective analysis from Leeds Cancer Centre

Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: Retrospective analysis from Leeds Cancer Centre
12    71    0
Association of differential miRNA expression with hepatic vs. peritoneal metastatic spread in colorectal cancer

Association of differential miRNA expression with hepatic vs. peritoneal metastatic spread in colorectal cancer
10    58    0
Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: A retrospective study

Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: A retrospective study
7    81    0
A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)

A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)
9    100    0
The prognostic significance of the advanced lung cancer inflammation index in patients with unresectable metastatic colorectal cancer: A retrospective study

The prognostic significance of the advanced lung cancer inflammation index in patients with unresectable metastatic colorectal cancer: A retrospective study
8    52    0
Genomic alterations accompanying tumour evolution in colorectal cancer: Tracking the differences between primary tumours and synchronous liver metastases by wholeexome sequencing

Genomic alterations accompanying tumour evolution in colorectal cancer: Tracking the differences between primary tumours and synchronous liver metastases by wholeexome sequencing
13    67    0
A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer

A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer
10    70    0
Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer

Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer
10    52    0
Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan

Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
9    52    0
Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer

Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer
10    53    0
Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: An open-label, multi-center, non-comparative phase II study

Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: An open-label, multi-center, non-comparative phase II study
8    62    0
Whole-body total lesion glycolysis measured on fluorodeoxyglucose positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer

Whole-body total lesion glycolysis measured on fluorodeoxyglucose positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer
7    72    0
FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab

FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab
9    45    0
Comparison of survival of patients with metastases from known versus unknown primaries: Survival in metastatic cancer

Comparison of survival of patients with metastases from known versus unknown primaries: Survival in metastatic cancer
8    55    0
Real-world effectiveness of posttrastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: A retrospective observational study (KBCSGTR 1917)

Real-world effectiveness of posttrastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: A retrospective observational study (KBCSGTR 1917)
12    84    1
Corticosteroid switch from prednisone to dexamethasone in metastatic castrationresistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone

Corticosteroid switch from prednisone to dexamethasone in metastatic castrationresistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone
9    73    1
Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment

Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
9    21    1
Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential

Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential
15    57    0
Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer

Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer
6    64    0
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.